Physician profile
David E Sowa
NPI 1104813377
$4,691.64
in general payments reported to CMS, 2019-2025
32 companies · $521 in 2025
The $521 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $303 · 2021: $330 · 2022: $747 · 2023: $951 · 2024: $947 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.78 | 2019-2024 | Lo Loestrin Fe |
| Astellas Pharma US INC | $567.36 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $316.63 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $304.59 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $282.65 | 2019-2022 | |
| Exact Sciences Corporation | $256.30 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $239.80 | 2019-2025 | Gardasil 9, Gardasil |
| Pfizer INC. | $228.86 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $220.57 | 2022-2024 | |
| Millicent US INC | $212.53 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Myovant Sciences INC. | $197.57 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $145.52 | 2023-2025 | Myfembree, Gemtesa |
| Duchesnay USA Incorporated | $111.55 | 2019 | |
| Coopersurgical, INC. | $106.04 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Sage Therapeutics, LLC | $101.00 | 2024-2025 | Zurzuvae |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $96.88 | 2019-2020 | |
| Organon LLC | $86.75 | 2022-2025 | Nexplanon |
| Mylan Pharmaceuticals INC. | $86.39 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.47 | 2021-2023 | |
| Daiichi Sankyo INC. | $77.06 | 2019-2024 | Injectafer |
| Amag Pharmaceuticals, INC. | $74.88 | 2019-2020 | |
| Urovant Sciences INC | $44.14 | 2022 | |
| Avion Pharmaceuticals | $36.77 | 2019-2020 | |
| Allergan, INC. | $28.55 | 2019 | |
| Aspira Women'S Health INC | $26.22 | 2019 | |
| Evofem Biosciences, INC. | $24.49 | 2020 | |
| Supernus Pharmaceuticals, INC. | $23.81 | 2025 | Qelbree |
| Scynexis, INC. | $19.69 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.58 | 2019 | |
| Abbott Laboratories | $15.50 | 2023 | Freestyle Libre 3 |
| Sanara Medtech INC. | $14.87 | 2024 | Celleraterx |
| Roche Diagnostics Corporation | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sowa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.